Abstract
Most patients diagnosed with non-small cell lung cancer (NSCLC) have advanced disease. Chemotherapy has apparently reached a plateau of effectiveness in improving survival in this subgroup of patients. Considerable efforts have been initiated to identify novel targets for new biological agents which may be safely and effectively administered to NSCLC patients. New blood vessel formation, known as angiogenesis, is a fundamental event in the process of tumor growth and metastatic dissemination. The vascular endothelial growth factor (VEGF) and its receptors play an essential role in tumor proliferation. Approaches to limit VEGF activity include monoclonal antibodies (mAbs) and small molecules inhibiting the corresponding receptor-tyrosine kinase activity. Bevacizumab, an anti-VEGF recombinant humanized mAb, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced NSCLC. Future clinical developments of bevacizumab in NSCLC treatment include the combination with other targeted therapies in advanced disease, and the integration into the combined modality approaches for the treatment of early and locally advanced disease stages. Vandetanib, a small molecule targeting VEGF tyrosine-kinase activity, due to first indications of antitumor activity and the excellent toxicity profile seems to be a promising agent for the treatment of advanced NSCLC. Other antiangiogenic drugs, such as sorafenib, sunitinib, VEGF Trap and a new class named ‘vascular disrupting agents’, which includes ASA404, are being tested in ongoing clinical trials which will further define their role in the management of NSCLC.
Keywords: NSCLC, bevacizumab, ZD6474, sorafenib, sunitinib, VEGF Trap, vascular disrupting agents, ASA404
Current Medicinal Chemistry
Title: Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Volume: 16 Issue: 30
Author(s): A. Rossi, P. Maione, M. L. Ferrara, P. C. Sacco, C. Schettino, M. A. Bareschino and C. Gridelli
Affiliation:
Keywords: NSCLC, bevacizumab, ZD6474, sorafenib, sunitinib, VEGF Trap, vascular disrupting agents, ASA404
Abstract: Most patients diagnosed with non-small cell lung cancer (NSCLC) have advanced disease. Chemotherapy has apparently reached a plateau of effectiveness in improving survival in this subgroup of patients. Considerable efforts have been initiated to identify novel targets for new biological agents which may be safely and effectively administered to NSCLC patients. New blood vessel formation, known as angiogenesis, is a fundamental event in the process of tumor growth and metastatic dissemination. The vascular endothelial growth factor (VEGF) and its receptors play an essential role in tumor proliferation. Approaches to limit VEGF activity include monoclonal antibodies (mAbs) and small molecules inhibiting the corresponding receptor-tyrosine kinase activity. Bevacizumab, an anti-VEGF recombinant humanized mAb, is the first targeted agent which, when combined with chemotherapy, has shown superior efficacy versus chemotherapy alone as first-line treatment of advanced NSCLC. Future clinical developments of bevacizumab in NSCLC treatment include the combination with other targeted therapies in advanced disease, and the integration into the combined modality approaches for the treatment of early and locally advanced disease stages. Vandetanib, a small molecule targeting VEGF tyrosine-kinase activity, due to first indications of antitumor activity and the excellent toxicity profile seems to be a promising agent for the treatment of advanced NSCLC. Other antiangiogenic drugs, such as sorafenib, sunitinib, VEGF Trap and a new class named ‘vascular disrupting agents’, which includes ASA404, are being tested in ongoing clinical trials which will further define their role in the management of NSCLC.
Export Options
About this article
Cite this article as:
Rossi A., Maione P., Ferrara L. M., Sacco C. P., Schettino C., Bareschino A. M. and Gridelli C., Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer, Current Medicinal Chemistry 2009; 16 (30) . https://dx.doi.org/10.2174/092986709789352286
DOI https://dx.doi.org/10.2174/092986709789352286 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Molecular Mechanisms Regulating mRNA Stability: Physiological and Pathological Significance
Current Genomics Chemoprevention Strategies for High Risk Women
Current Women`s Health Reviews The Genus Glycosmis [Rutaceae]: A Comprehensive Review on its Phytochemical and Pharmacological Perspectives
The Natural Products Journal Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs
Current Drug Metabolism Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Future Oncotargets: Targeting Overexpressed Conserved Protein Targets in Androgen Independent Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Drug Delivery by Means of Lipid Nanoparticles: Reality or İllusion?
Current Pharmaceutical Design Store-Operated Ca2+ Entry in Muscle Physiology
Current Chemical Biology Synthesis and Pharmacological Evaluation of Maleopimaric N-arylimides: Identification of Novel Proapoptotic Agents
Anti-Cancer Agents in Medicinal Chemistry Thin Metal Films in Resistivity-based Chemical Sensing
Current Analytical Chemistry Emerging Immunotargets in Bladder Cancer
Current Drug Targets Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Electrohydrodynamic Preparation of Nanomedicines
Current Topics in Medicinal Chemistry Angiotensin-(1-7): A Peptide Hormone with Anti-Cancer Activity
Current Medicinal Chemistry The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design